CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$1.52 USD
-0.15 (-8.98%)
Updated Sep 23, 2025 04:00 PM ET
After-Market: $1.58 +0.06 (3.95%) 5:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CASI 1.52 -0.15(-8.98%)
Will CASI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CASI
Veeva Systems (VEEV) Surpasses Q2 Earnings and Revenue Estimates
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
CASI forms Lower Bollinger Band Walk on September 22
CASI forms MACD Bearish Centerline Cross on September 19
Fell Below 50 Day Moving Average appears for CASI after 6.56% move
CASI forms Lower Bollinger Band Walk on September 17
Is CASI gathering momentum? Narrow Range Bar shows up after sliding 3.83%